Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder…
An institutional-grade, numbers-driven thesis on ANRO — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 16, 2026, TradersQuant's model rates Alto Neuroscience, Inc. (ANRO) 63/100 with a 12-month base-case forecast of $36.40 — +13.3% versus the current price of $32.14. Alto Neuroscience, Inc. trades at $32.14 in the Healthcare sector, with a market capitalisation of $1.13B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for ANRO is $36.40, implying +13.3% versus the current price. The model's 12-month scenario range runs from $49.34 (bear) to $62.02 (bull), with a base case of $53.95.
On the fundamentals, Alto Neuroscience shows a P/E of -13.0, trailing revenue of $0, revenue growth of +0.0% YoY. This page also tracks ANRO's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
ANRO currently carries a TradersQuant composite score of 63/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $36.40 implies +13.3% from $32.14. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for ANRO is $36.40, about +13.3% versus the latest price of $32.14. Consensus is based on 9 analysts.
TradersQuant's 12-month model forecast for ANRO is a base case of $53.95, ranging from $49.34 (bear) to $62.02 (bull), an expected return of +67.9%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for ANRO over the next 12 months is $53.95 in the base case (bear $49.34, bull $62.02), versus today's price of $32.14. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for ANRO — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates ANRO's fair value at $36.40, implying +13.3% of expected upside versus the current price.
Alto Neuroscience does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
